Literature DB >> 25411445

WWOX-related encephalopathies: delineation of the phenotypical spectrum and emerging genotype-phenotype correlation.

Cyril Mignot1, Laetitia Lambert2, Laurent Pasquier3, Thierry Bienvenu4, Andrée Delahaye-Duriez5, Boris Keren1, Jérémie Lefranc6, Aline Saunier7, Lila Allou8, Virginie Roth7, Mylène Valduga7, Aissa Moustaïne7, Stéphane Auvin9, Catherine Barrey10, Sandra Chantot-Bastaraud11, Nicolas Lebrun4, Marie-Laure Moutard12, Marie-Christine Nougues12, Anne-Isabelle Vermersch13, Bénédicte Héron14, Eva Pipiras5, Delphine Héron1, Laurence Olivier-Faivre15, Jean-Louis Guéant8, Philippe Jonveaux16, Christophe Philippe16.   

Abstract

BACKGROUND: Homozygous mutations in WWOX were reported in eight individuals of two families with autosomal recessive spinocerebellar ataxia type 12 and in two siblings with infantile epileptic encephalopathy (IEE), including one who deceased prior to DNA sampling.
METHODS: By combining array comparative genomic hybridisation, targeted Sanger sequencing and next generation sequencing, we identified five further patients from four families with IEE due to biallelic alterations of WWOX.
RESULTS: We identified eight deleterious WWOX alleles consisting in four deletions, a four base-pair frameshifting deletion, one missense and two nonsense mutations. Genotype-phenotype correlation emerges from the seven reported families. The phenotype in four patients carrying two predicted null alleles was characterised by (1) little if any psychomotor acquisitions, poor spontaneous motility and absent eye contact from birth, (2) pharmacoresistant epilepsy starting in the 1st weeks of life, (3) possible retinal degeneration, acquired microcephaly and premature death. This contrasted with the less severe autosomal recessive spinocerebellar ataxia type 12 phenotype due to hypomorphic alleles. In line with this correlation, the phenotype in two siblings carrying a null allele and a missense mutation was intermediate.
CONCLUSIONS: Our results obtained by a combination of different molecular techniques undoubtedly incriminate WWOX as a gene for recessive IEE and illustrate the usefulness of high throughput data mining for the identification of genes for rare autosomal recessive disorders. The structure of the WWOX locus encompassing the FRA16D fragile site might explain why constitutive deletions are recurrently reported in genetic databases, suggesting that WWOX-related encephalopathies, although likely rare, may not be exceptional. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  genotype/phenotype correlations; high throughput data mining; infantile; intellectual disability

Mesh:

Substances:

Year:  2014        PMID: 25411445     DOI: 10.1136/jmedgenet-2014-102748

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  27 in total

1.  WWOX-associated encephalopathies: identification of the phenotypic spectrum and the resulting genotype-phenotype correlation.

Authors:  Hepsen Mine Serin; Erdem Simsek; Esra Isik; Sarenur Gokben
Journal:  Neurol Sci       Date:  2018-08-09       Impact factor: 3.307

2.  Novel mutations in WWOX, RARS2, and C10orf2 genes in consanguineous Arab families with intellectual disability.

Authors:  Asem M Alkhateeb; Samah K Aburahma; Wesal Habbab; I Richard Thompson
Journal:  Metab Brain Dis       Date:  2016-04-28       Impact factor: 3.584

3.  A novel missense variant in the SDR domain of the WWOX gene leads to complete loss of WWOX protein with early-onset epileptic encephalopathy and severe developmental delay.

Authors:  Jessika Johannsen; Fanny Kortüm; Georg Rosenberger; Kristin Bokelmann; Markus A Schirmer; Jonas Denecke; René Santer
Journal:  Neurogenetics       Date:  2018-05-28       Impact factor: 2.660

4.  WWOX and severe autosomal recessive epileptic encephalopathy: first case in the prenatal period.

Authors:  Mylène Valduga; Christophe Philippe; Laetitia Lambert; Pascale Bach-Segura; Emmanuelle Schmitt; Jean Pierre Masutti; Bénédicte François; Patrick Pinaud; Mireille Vibert; Philippe Jonveaux
Journal:  J Hum Genet       Date:  2015-02-26       Impact factor: 3.172

5.  Rare Inherited and De Novo CNVs Reveal Complex Contributions to ASD Risk in Multiplex Families.

Authors:  Virpi M Leppa; Stephanie N Kravitz; Christa Lese Martin; Joris Andrieux; Cedric Le Caignec; Dominique Martin-Coignard; Christina DyBuncio; Stephan J Sanders; Jennifer K Lowe; Rita M Cantor; Daniel H Geschwind
Journal:  Am J Hum Genet       Date:  2016-08-25       Impact factor: 11.025

6.  Wwox deletion leads to reduced GABA-ergic inhibitory interneuron numbers and activation of microglia and astrocytes in mouse hippocampus.

Authors:  Tabish Hussain; Hyunsuk Kil; Bharathi Hattiangady; Jaeho Lee; Maheedhar Kodali; Bing Shuai; Sahithi Attaluri; Yoko Takata; Jianjun Shen; Martin C Abba; Ashok K Shetty; C Marcelo Aldaz
Journal:  Neurobiol Dis       Date:  2018-10-02       Impact factor: 5.996

7.  Early infantile-onset epileptic encephalopathy 28 due to a homozygous microdeletion involving the WWOX gene in a region of uniparental disomy.

Authors:  Mariska Davids; Thomas Markello; Lynne A Wolfe; Xenia Chepa-Lotrea; Cynthia J Tifft; William A Gahl; May Christine V Malicdan
Journal:  Hum Mutat       Date:  2018-11-18       Impact factor: 4.878

Review 8.  Pleiotropic Functions of Tumor Suppressor WWOX in Normal and Cancer Cells.

Authors:  Muhannad Abu-Remaileh; Emma Joy-Dodson; Ora Schueler-Furman; Rami I Aqeilan
Journal:  J Biol Chem       Date:  2015-10-23       Impact factor: 5.157

Review 9.  Advancing epilepsy genetics in the genomic era.

Authors:  Candace T Myers; Heather C Mefford
Journal:  Genome Med       Date:  2015-08-25       Impact factor: 11.117

10.  Tumor Suppressor WWOX inhibits osteosarcoma metastasis by modulating RUNX2 function.

Authors:  Sara Del Mare; Rami I Aqeilan
Journal:  Sci Rep       Date:  2015-08-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.